Delivery Order SPE2DB25D3404-SPE2DB25FUQTP
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,927.33 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on April 24, 2025, with completion scheduled for April 25, 2025. This firm fixed-price, competitively awarded delivery order represents a continuation of AmerisourceBergen's substantial role as a critical pharmaceutical supplier to the federal government. The order will be fulfilled from the contractor's location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,048.25 for Zepbound 10 mg/0.5 mL pen injectors on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a continuation of AmerisourceBergen's extensive pharmaceutical supply...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $3,431.61 on August 21, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed-price, non-set-aside delivery order is scheduled for completion by August 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a small-value transaction under AmerisourceBergen's larger relationship...
- The Defense Logistics Agency awarded a delivery order valued at $9,527.57 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 ml pen injectors on August 1, 2025. This firm fixed-price, competitively awarded delivery order represents a non-set-aside procurement and is scheduled for completion by August 4, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $6,100.64. This firm fixed-price delivery order, with an ultimate completion date of September 11, 2025, represents a small-value pharmaceutical procurement executed through the DLA's medical supply chain. The award was made on a competitive basis with no set-aside designation, and the product will be delivered to...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors with a ceiling value of $2,696.06. This is a firm fixed-price, non-set-aside delivery order with a completion date of June 3, 2025, with performance to be fulfilled at the vendor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal...
- The Defense Logistics Agency awarded a delivery order valued at $9,303.51 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 ml pen injectors on September 12, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price, non-set-aside delivery order represents a routine pharmaceutical procurement under the company's larger contract vehicle with DLA. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $14,108.65 on September 9, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens. This firm fixed-price delivery order, which is not set-aside and competitively awarded, is scheduled for completion by September 10, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical supplier...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,797.29 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on September 26, 2025, with completion expected by September 29, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $15,184.50 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injectors on July 24, 2025, with completion expected by July 25, 2025. This firm fixed-price, competitively awarded delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government. The award was issued without set-aside designation, reflecting open competition among qualified vendors. This...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB25FUQTPDelivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $9,591.59 on September 26, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors (0.5 mL units). This firm fixed price, non-set-aside delivery order is scheduled for completion by September 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's critical role as a pharmaceutical distributor supporting federal medical procurement needs. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical supplies to military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates extensive experience fulfilling diverse pharmaceutical requirements for the Defense Health Agency and other government healthcare systems through competitively awarded contracts with firm fixed pricing structures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.6k | 9/26/25 |